StockData
CBLLNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31

Ceribell, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026
$26.00+0.96 (+3.83%)

Close on Oct 19, 2026

Market cap
$988.83M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 3, 2026, after market close (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 10, 2026After market close$28.10M$-0.51–
Q1 FY2026
Ended Mar 31, 2026
May 11, 2026After market close$26.50M$-0.52–
Q4 FY2025
Ended Dec 31, 2025
Feb 24, 2026After market close$24.80M$-0.36–
Q3 FY2025
Ended Sep 30, 2025
Nov 4, 2025After market close$22.60M$-0.37–
Q2 FY2025
Ended Jun 30, 2025
Aug 5, 2025After market close$21.20M$-0.38–
Q1 FY2025
Ended Mar 31, 2025
May 8, 2025After market close$20.50M$-0.36–
Q4 FY2024
Ended Dec 31, 2024
Feb 25, 2025After market close$18.50M$-0.40–
Q3 FY2024
Ended Sep 30, 2024
Nov 12, 2024After market close$17.20M$-1.85–

Company guidance

Outlook given with results on Aug 10, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
growthfull year 202628% to 31% growthNew
revenuefull year 2026$114.00M to $117.00MRaised

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Ceribell filed with the SEC